This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg, Imported And Distributed By The Laboratory Chemical Pharmaceutical Bergamo Ltda., Compared To Product Sandostatin LAR ® (Octreotide Acetate LAR) 30 MG Manufactured By Novartis Biosciences S / A.

This study has suspended participant recruitment.
Information provided by:
Azidus Brasil Identifier:
First received: March 12, 2010
Last updated: October 26, 2010
Last verified: March 2010
Check the pharmacodynamics of the drug octreotide acetate LAR 30 mg imported and distributed by Chemical Laboratory Pharmaceutical Bergamo Ltda. compared to the drug Sandostatin LAR ® (octreotide acetate 30 mg) manufactured by Novartis Biociências S / A, using as activity analysis of growth hormone (GH) and growth factor insulin-like 1 (IGF-1 ) after a single dose of the drug in patients with acromegaly

Condition Intervention Phase
Acromegaly Drug: Octreotide acetate LAR Drug: Sandostatin LAR ® (octreotide acetate LAR) 30 MG Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Azidus Brasil:

Primary Outcome Measures:
  • Quantification of serum levels of GH and IGF-I. [ Time Frame: Before drug administration, after drug administration, 1, 3, 7, 14, 21, 28, 35, 42, 49, 56 and 63 days after. ]

Secondary Outcome Measures:
  • Occurrence and severity of side effects during use of the product in order to ensure the security of it. [ Time Frame: After drug administration, 1, 3, 7, 14, 21, 28, 35, 42, 49, 56 and 63 days after. ]

Estimated Enrollment: 16
Study Start Date: March 2010
Estimated Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Octreotide acetate LAR 30 MG
Drug: Octreotide acetate LAR
30 mg, single dose
Active Comparator: Sandostatin LAR ® (octreotide acetate LAR) 30 MG Drug: Sandostatin LAR ® (octreotide acetate LAR) 30 MG
30 mg, single dose

Detailed Description:
Secondly, it will be observed safety (tolerability) in clinical patients by comparing the clinical and laboratory parameters before and after the study and the incidence of adverse events after a single dose

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

- Accept the Terms of Consent;

  • be aged over 18, regardless of sex;
  • Patients with acromegaly who presented GH levels ≥ 2.5 ng / mL or no suppression of GH levels to less than 1 ng / mL after tolerance test glucose and IGF-I levels for age and sex;
  • Patients undergoing hypophysectomy followed by radiotherapy or not and to keep níves increased GH and IGF-I;
  • Patients waiting hypophysectomy with increased levels of GH and IGF-I

Exclusion Criteria:

  • Have participated in any experimental study or have ingested any drug trial within six months prior to the start of the study;
  • Have made use of medications that influence the results, regular 4 weeks prior to the start of the study or having used any medication a week before the start of the study;
  • Have been treated with somastostatina analog or dopamine agonist in the last 2 months;
  • Present history of myocardial infarction, angina and / or heart failure;
  • Patients who present calculation of the gallbladder and have not undergone cholecystectomy;
  • Pregnant women and nursing;
  • Patients who have allergies to medicine;
  • Patients with a history of acute pancreatitis;
  • Patient with altered levels of amylase
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01086982

LAL Clínica Pesquisa e Desenvolvimento Ltda
Valinhos, São Paulo, Brazil
Sponsors and Collaborators
Azidus Brasil
  More Information

Responsible Party: Alexandre Frederico, LAL Clínica Pesquisa e Desenvolvimento Ltda Identifier: NCT01086982     History of Changes
Other Study ID Numbers: OCTBER0409
Version 3
Study First Received: March 12, 2010
Last Updated: October 26, 2010

Additional relevant MeSH terms:
Bone Diseases, Endocrine
Bone Diseases
Musculoskeletal Diseases
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Gastrointestinal Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents processed this record on September 21, 2017